The LADI clinical trial (NCT03172377) aimed to demonstrate non-inferiority and cost-effectiveness of extending the adalimumab dosing interval in patients with Crohn’s disease in stable remission, when compared to standard dosing. We caught up with Reinier van Linschoten (Franciscus Gasthuis & Vlietland; and Erasmus MC, Rotterdam, the Netherlands) to discuss the aims, design, eligibility criteria and findings of the LADI clinical trial.
The abstract entitled ‘CLINICAL OUTCOMES OF INCREASED VERSUS CONVENTIONAL ADALIMUMAB DOSE INTERVALS IN PATIENTS WITH CROHN’S DISEASE IN STABLE REMISSION: THE RANDOMISED CONTROLLED LADI TRIAL’ (Abstract no: OP106) was presented at UEG Week, October 8 – 11, 2022.
Questions
- What were the aims, design and eligibility criteria of the LADI clinical trial? (0:22)
- What were the primary and secondary outcome measures, and how well were they achieved in the two treatment groups? (1:54)
- On the basis of these findings, should the dose interval be increased and if so, in which patients? (4:22)
Disclosures: Reinier van Linschoten has nothing to disclose in relation to this video interview.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.
Filmed as a highlight of UEG Week 2022.
